These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8955602)

  • 41. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
    Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
    Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen receptor determination in fine needle aspirates of the breast. Correlation with histologic grade and comparison with biochemical analysis.
    Lozowski MS; Mishriki Y; Chao S; Grimson R; Pai P; Harris MA; Lundy J
    Acta Cytol; 1987; 31(5):557-62. PubMed ID: 3314302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
    Lorgis V; Algros MP; Villanueva C; Chaigneau L; Thierry-Vuillemin A; Nguyen T; Demarchi M; Bazan F; Sautiere JL; Maisonnette-Lescot Y; Ringenbach F; Bontemps P; Pivot X
    Breast; 2011 Jun; 20(3):284-7. PubMed ID: 21288720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
    Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.
    Arihiro K; Umemura S; Kurosumi M; Moriya T; Oyama T; Yamashita H; Umekita Y; Komoike Y; Shimizu C; Fukushima H; Kajiwara H; Akiyama F
    Am J Clin Pathol; 2007 Mar; 127(3):356-65. PubMed ID: 17276950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Axillary staging by percutaneous biopsy: sensitivity of fine-needle aspiration versus core needle biopsy.
    Rao R; Lilley L; Andrews V; Radford L; Ulissey M
    Ann Surg Oncol; 2009 May; 16(5):1170-5. PubMed ID: 19263171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period.
    Ng WK
    Cancer; 2002 Oct; 96(5):280-8. PubMed ID: 12378595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of fine needle aspirates in the evaluation of progesterone receptor content in breast cancer.
    Lozowski M; Greene GL; Sadri D; Stanick D; Pai P; Harris MA; Lundy J
    Acta Cytol; 1990; 34(1):27-30. PubMed ID: 2404374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Drill biopsy and puncture biopsy for the determination of hormone receptors].
    Magdelenat H
    Pathol Biol (Paris); 1983 Nov; 31(9):755-60. PubMed ID: 6361673
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.
    Penault-Llorca F; Cayre A; Bouchet Mishellany F; Amat S; Feillel V; Le Bouedec G; Ferrière JP; De Latour M; Chollet P
    Int J Oncol; 2003 Jun; 22(6):1319-25. PubMed ID: 12739000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunocytochemical evaluation of estrogen receptor on archival Papanicolaou-stained fine-needle aspirate smears.
    Krishnamurthy S; Dimashkieh H; Patel S; Sneige N
    Diagn Cytopathol; 2003 Dec; 29(6):309-14. PubMed ID: 14648786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Semi-quantitative RT-PCR assessment of molecular markers in breast large-core needle biopsies.
    Pohlodek K; Galbavý S; Bartosová M; Mucha V; Holomán K; Pastorek J; Pastoreková S
    Neoplasma; 2004; 51(6):415-21. PubMed ID: 15640949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
    Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma.
    Gong Y; Symmans WF; Krishnamurthy S; Patel S; Sneige N
    Cancer; 2004 Feb; 102(1):34-40. PubMed ID: 14968416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of mastectomy techniques on estrogen and progesterone receptor analysis in carcinoma of the breast.
    Rodier JF; Millon R; Janser JC; Rodier D; Velten M; Pusel J; Eber M; Abecassis J
    Surg Gynecol Obstet; 1993 Oct; 177(4):352-6. PubMed ID: 8211577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A subset of breast invasive ductal carcinoma with distinctive cytomorphology, aggressive clinical behavior, and unique immunologic profiles.
    Lu D; Masood S; Khalbuss WE; Bui M
    Cancer; 2002 Oct; 96(5):294-300. PubMed ID: 12378597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.